For more information, see the announcement here.

Press Release – 

London: Tuesday, 7 October 2014:  Chi-Med today announces that it will host a briefing to update analysts and investors on Hutchison MediPharma Limited (“HMP”), its majority owned pharmaceutical R&D division, in London on 17 October 2014. HMP has a substantial pipeline of oral, small molecule and botanical drugs for cancer and inflammatory diseases that has grown and progressed significantly in recent years.

HMP’s current clinical pipeline includes: fruquintinib, sulfatinib, epitinib, theliatinib, and AZD6094 (formerly known as volitinib), each of which has the potential to treat a number of cancers. The clinical pipeline also includes HMPL‑523 and HMPL‑004, which have potential to treat certain inflammatory conditions.  The briefing will focus on this pipeline.

During the briefing, the management team will detail the key aspects of HMP’s R&D strategy and focus, as well as providing further information on some of HMP’s pre-clinical research programmes, including its PI3Kδ inhibitor and its FGFR inhibitor.

The briefing will begin with a keynote presentation from Dr Andrew Mortlock, Vice President of Cancer Research and Development Projects of AstraZeneca, entitled, “Next Generation Kinase Inhibitors for the Treatment of Cancer.”  He is responsible for AstraZeneca’s small molecule oncology projects from lead optimization to the end of Phase IIb.

Dr Weiguo Su, Executive Vice President and Chief Scientific Officer of HMP and Dr Ye Hua, Senior Vice President of Clinical Development & Regulatory Affairs of HMP, will be presenting on HMP’s compounds in research & development and HMP’s overall strategy.

Dr Su has 24 years of experience in delivering high quality new drug candidates at HMP and at Pfizer, where he was Director of Medicinal Chemistry.  Dr Su has built HMP’s highly productive research platform, including managing the discovery of all its small molecule drug candidates.

Dr Hua has over 15 years of new drug development and registration experience, as well as many years of experience in cancer epidemiology.  In the course of his career he has led several clinical teams in pursuing registration clinical trials and achieving regulatory approval for major marketed pharmaceuticals at Novartis and Celgene.

Mr Christian Hogg, Chief Executive Officer of Chi-Med, will also give presentations covering Chi-Med’s overall business strategy and approach to funding its R&D.

No new material trading or financial information will be disseminated at the meeting.  Following the meeting, the presentations will be made available at http://chi-med.com/eng/irinfo/presentations.htm.

The briefing will take place at the Andaz Hotel, 40 Liverpool Street, London, EC2M 7QN on 17 October 2014 at 9:30am, with registration starting from 9:15am.  Please contact Mrs Janine Chase by email at Janine.Chase@citigatedr.co.uk to register.

Ends

Enquiries

Notes to Editors

About HMP

HMP is a novel drug R&D division focusing on discovering, developing and commercialising innovative therapeutics in oncology and autoimmune diseases.  With a team of around 200 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.

HMP is majority owned by Chi-Med.  For more information, please visit: www.hmplglobal.com.

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

Press Release – 

London: Wednesday, 1 October 2014: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Chi-Med, through its subsidiary Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited (“Hutchison Sinopharm”), has signed a co-promotion agreement with Merck Serono Co., Ltd. (“Merck Serono”) a subsidiary of Merck in China to market certain cardiovascular prescription drug products in China.

Hutchison Sinopharm will exclusively co-promote Merck Serono’s Bisoprolol Fumarate tablets, under the Concor^® trademark, in several provinces in China. Concor^® is a major brand in the beta-blocker sub-segment of the cardiovascular prescription drug market in China.

Chi-Med today operates a commercial network in China of approximately 1,600 cardiovascular market focused medical sales representatives, covering more than 13,000 hospitals, through its joint ventures, Shanghai Hutchison Pharmaceuticals Limited and Hutchison Sinopharm.

Ends

Enquiries

About Chi-Med

 Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

 Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

About Merck Serono China

 With over 1,300 employees and a nationwide presence, Merck Serono is dedicated to serving the Chinese market. Merck Serono currently markets 15 products in 8 therapeutic areas in China. Merck Serono China is No.1 in fertility and thyroid therapeutic areas, and has strong presence in cardiovascular, endocrinology, oncology and NDD diseases.